Sven Andreasson joins Novavax as SVP of Corporate Development

Formerly CEO of Isconova, which was acquired by Novavax last year

Novavax, a US-based clinical-stage biopharmaceutical company focused on the development of recombinant nanoparticle vaccines and adjuvants, has appointed Sven Andreasson as Senior Vice President, Corporate Development, effective from 2 June.

Andreasson has a long history of experience in biopharmaceutical operations, executive management and strategic development. From 2012 to 2013 he was Chief Executive of Isconova in Uppsala, Sweden, an international vaccine adjuvant company acquired by Novavax in 2013. Before that he was Chief Executive of Beta-Cell in Brussels, Belgium from 2008 to 2012 and Chief Executive of Active Biotech in Lund, Sweden from 1999 to 2008. He also spent a number of years at Pharmacia Corporation.

You may also like

Research & Development

Alternating vaccines trial expands to include two additional vaccines

Volunteers, who will have received either the Oxford-AstraZeneca, or Pfizer vaccine, will be randomly allocated to receive either the same vaccine for their second dose, or a dose of the COVID-19 vaccines produced by Moderna or Novavax
You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Zika outbreak gives rise to global fears

Zika may not be a new virus but its newly confirmed ability to cause foetal brain abnormalities makes the search for a treatment or a vaccine a high priority. Dr Sarah Houlton looks at the latest initiatives
Research & Development

Novavax vaccine candidate produces immune response against deadly virus

Study by University of Maryland School of Medicine highlights potential effective means for preventing MERS-CoV
Research & Development

Novavax, CPL Biologicals and ICGEB to develop malaria vaccine

Will combine Novavax VLP vaccine technology with CPLB manufacturing and ICGEB research capabilities
Manufacturing

Novavax signs long-term lease on vaccine plant

Will relocate corporate hq to same campus in Gaithersburg
Research & Development

US HHS awards influenza contracts worth US$215m

Novavax and VaxInnate to develop VLP and recombinant influenza vaccines, respectively
Regulatory

FDA clears Novavax RSV vaccine candidate for early stage trial

Novavax resolves question about chemistry, manufacturing and controls
Subscribe now